i titrated over twice as many weeks as i did on semaglutide and that was right for me
#cagrilintide 2026-03-18
Wednesday22 messages6 participantstimes are UTC
Highlights from this day
- VialBot — Assay note: QSC lot SG-1177 reported at 99% of label content. 17:10
- electrolyte_eli — combination GI was worse than either alone for me, which is not what i had read anywhere, take that with a pinch of salt 17:30
- coa_or_cope — its an amylin analogue, different receptor family, so treating it as another GLP-1 is the first mistake 19:20
Assay note: QSC lot SG-1177 reported at 99% of label content.
combination GI was worse than either alone for me, which is not what i had read anywhere, take that with a pinch of salt
⚠️4👍6
the fullness thing is the part people describe differently, food stops being interesting rather than repellent
👍5
*Janoshik not the other one
held mine a while
fullness rather than nausea
CagriSema is cagrilintide with semaglutide and REDEFINE is the trial programme around it
the fullness effect hasnt faded over 18 months, unlike my semaglutide appetite curve
nobody should copy my schedule, im describing it because people asked what a slow ramp looks like
the combination is the thing with trial data behind it, monotherapy in here is mostly us guessing
changed my mind on this, i started thinking amylin was the interesting bit and now i think its the pairing, someone check my working
cagrisema thats it
⚠️7🧊7
the numbers everyone quotes come from the combination, so comparing them to monotherapy logs is unfair
[edited]is the weekly schedule the same here
noticed something around week 34 on monotherapy, well after i had given up expecting to
i keep the two on separate days so if something goes wrong i have a chance of knowing which
its an amylin analogue, different receptor family, so treating it as another GLP-1 is the first mistake
⚠️12
amylin not glp-1
anyone dosing this on a different day to their tirzepatide
monotherapy here
thats the phase 3 one
⚠️1
different not less